CA2308082A1 - Injectable compostion - Google Patents
Injectable compostion Download PDFInfo
- Publication number
- CA2308082A1 CA2308082A1 CA002308082A CA2308082A CA2308082A1 CA 2308082 A1 CA2308082 A1 CA 2308082A1 CA 002308082 A CA002308082 A CA 002308082A CA 2308082 A CA2308082 A CA 2308082A CA 2308082 A1 CA2308082 A1 CA 2308082A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- composition
- matter
- taxol
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Abstract
A composition of taxol and polyethoxylated castor oil is pH balanced to have a pH less than 8.1 to improve stability. This composition can include an acid, preferably citric acid, to adjust the pH value.
The invention includes a method of formulating a taxol solution for injection by mixing an acid with a carrier material, such as castor oil, to form a carrier solution after which taxol is mixed with the carrier solution to form the taxol solution at a pH of less than 8.1. The method may include the step of slurrying the taxol in alcohol before mixing with the carrier solution.
The invention includes a method of formulating a taxol solution for injection by mixing an acid with a carrier material, such as castor oil, to form a carrier solution after which taxol is mixed with the carrier solution to form the taxol solution at a pH of less than 8.1. The method may include the step of slurrying the taxol in alcohol before mixing with the carrier solution.
Description
INJECTABLE COMPOSITION
This invention relates to a solution of taxol having improved stability.
This application is a division of copending Canadian Patent Application No. 2,149,150 filed November 18, 1993.
Taxol is a compound extracted from the bark of a western yew, Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049. "TAXOL" is a registered trade-mark for the substance paclitaxel.
In 1977, taxol was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-1 mammary tumor xenograft.
Taxol is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro. Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly. Taxol employs a different mechanism of action since it appears to shift the equilibrium of polymerization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules. The interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells.
After extensive preclinical screening in mouse tumor models, taxol entered clinical trials in 1983.
Over the past few years, taxol has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefiting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck.
5 For further information, reference may be made to the U.S. National Cancer Institute's Clinical Brochure for Taxol, revised July 1991, and papers presented at the Second National Cancer Institute Workshop on Taxol and Taxus held in Alexandria, Virginia USA on September 23-24, 1992.
It is a disadvantage of a known formulation that the taxol therein degrades, with the result that the shelf life of the formulation is unsatisfactory, and there is therefore a need for a taxol solution of improved stability.
In accordance with one aspect of the invention claimed in the parent application, there is provided an improvement in a pharmaceutical formulation adapted for use in treating cancer comprising taxol and polyethoxylated castor oil, the improvement comprising an acidifying agent added to the pharmaceutical formulation in a proportion such that the composition has a resulting pH less than or equal to 7Ø
In accordance with an aspect of the present invention, there is provided an article of manufacture comprising a sealable container and a pharmaceutical formulation contained therein, the pharmaceutical formulation comprising taxol; a pharmaceutically acceptable carrier; and an acid in sufficient amount to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for seven days; and wherein said pharmaceutical formulation has been sealed in said container for at least seven days.
In accordance with another aspect of the present invention, there is provided a composition of matter produced by the process of (a) obtaining a sealable container; (b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid in sufficient amount to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for seven days; (c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
In accordance with an additional aspect of the present invention, there is provided a composition of matter comprising a sealable container and a pharmaceutical formulation contained therein, said pharmaceutical formulation comprising taxol; a pharmaceutically-acceptable carrier; and an acid, said formulation being such that at least 95% of the taxol potency is retained when said formulation is stored at 40°C for seven days; and wherein said pharmaceutical formulation has been sealed in said container for at least seven days.
In accordance with a further aspect of the present invention, there is provided a composition of matter produced by the process of (a) obtaining a sealable container; (b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid, said formulation being such that at least 95% of the taxol potency is retained when said formulation is stored at 40°C for seven days; (c) placing said pharmaceutical formulation in said sealable container; (d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
Accordingly, in a general aspect the invention provides a solution containing taxol, cremophor ELTM
and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid. Acids in the form of powders, for example citric acid, are preferred over those which contain water, for example sulfuric acid . The most preferred acid for use in accordance with the present invention is citric acid but a wide range of acids may be used including the following:
Citric acid - monohydrous Citric acid - anhydrous Citric acid - hydrous Acetic acid Formic acid Ascorbic acid Aspartic acid Benzene sulphonic acid Benzoic acid Hydrochloric acid Sulphuric acid Phosphoric acid Nitric acid Tartaric acid Diatrizoic acid Glutamic acid Lactic acid Malefic acid Succinic acid 5 Due to its limited solubility in water, Taxol is usually prepared and administered in a vehicle containing cremophor ELTM (a polyethoxylated castor oil which acts as a solubilizer) and ethanol. A
commercially available solution supplied by Bristol-Myers Squibb (BMS) is formulated with these components and has a pH of 9.1.
As indicated above, the invention essentially teaches addition of an acid to a taxol formulation to adjust its pH into the range 1 to 8, preferably 5 to 7.
In a preferred procedure adopted by the applicant, which it will be clearly understood is non-limiting, the following steps were carried out:
Mixina Instructions Citric acid was dissolved in absolute alcohol, using a ratio of 8 mls of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes.
Cremophor EL was weighted out into the main mixing vessel.
Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid. Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes. The taxol was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of taxol. The slurried taxol was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol. Solution 3 was adjusted 5 to 75% of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes.
Exam~l a 1 A solution was prepared with the following formulation:
Formulation: (Sample 1) Cremophor EL 0.5 mL
Citric Acid (Anhydrous) 2.0 mg Taxol 6.0 mg Absolute Alcohol to 1.0 mL
The pH of this solution was determined as 6.1.
The stability of this sample was compared with a sample prepared by the formulation stated in the NCI
Taxol Clinical brochure (as follows) which had a pH of 9.1. (Sample 2) Sample 2 per mL
Taxol 6 mg Cremophor EL 0.5 mL
Absolute Alcohol to 1 mL
The solutions were filled into clear type 1 glass 5 mL vials and sealed with rubber bungs.
The solutions were stored at 40°C for 7 (seven) days and the stability results are shown in Table 1.
This invention relates to a solution of taxol having improved stability.
This application is a division of copending Canadian Patent Application No. 2,149,150 filed November 18, 1993.
Taxol is a compound extracted from the bark of a western yew, Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049. "TAXOL" is a registered trade-mark for the substance paclitaxel.
In 1977, taxol was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-1 mammary tumor xenograft.
Taxol is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro. Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly. Taxol employs a different mechanism of action since it appears to shift the equilibrium of polymerization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules. The interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells.
After extensive preclinical screening in mouse tumor models, taxol entered clinical trials in 1983.
Over the past few years, taxol has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefiting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck.
5 For further information, reference may be made to the U.S. National Cancer Institute's Clinical Brochure for Taxol, revised July 1991, and papers presented at the Second National Cancer Institute Workshop on Taxol and Taxus held in Alexandria, Virginia USA on September 23-24, 1992.
It is a disadvantage of a known formulation that the taxol therein degrades, with the result that the shelf life of the formulation is unsatisfactory, and there is therefore a need for a taxol solution of improved stability.
In accordance with one aspect of the invention claimed in the parent application, there is provided an improvement in a pharmaceutical formulation adapted for use in treating cancer comprising taxol and polyethoxylated castor oil, the improvement comprising an acidifying agent added to the pharmaceutical formulation in a proportion such that the composition has a resulting pH less than or equal to 7Ø
In accordance with an aspect of the present invention, there is provided an article of manufacture comprising a sealable container and a pharmaceutical formulation contained therein, the pharmaceutical formulation comprising taxol; a pharmaceutically acceptable carrier; and an acid in sufficient amount to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for seven days; and wherein said pharmaceutical formulation has been sealed in said container for at least seven days.
In accordance with another aspect of the present invention, there is provided a composition of matter produced by the process of (a) obtaining a sealable container; (b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid in sufficient amount to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for seven days; (c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
In accordance with an additional aspect of the present invention, there is provided a composition of matter comprising a sealable container and a pharmaceutical formulation contained therein, said pharmaceutical formulation comprising taxol; a pharmaceutically-acceptable carrier; and an acid, said formulation being such that at least 95% of the taxol potency is retained when said formulation is stored at 40°C for seven days; and wherein said pharmaceutical formulation has been sealed in said container for at least seven days.
In accordance with a further aspect of the present invention, there is provided a composition of matter produced by the process of (a) obtaining a sealable container; (b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid, said formulation being such that at least 95% of the taxol potency is retained when said formulation is stored at 40°C for seven days; (c) placing said pharmaceutical formulation in said sealable container; (d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
Accordingly, in a general aspect the invention provides a solution containing taxol, cremophor ELTM
and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid. Acids in the form of powders, for example citric acid, are preferred over those which contain water, for example sulfuric acid . The most preferred acid for use in accordance with the present invention is citric acid but a wide range of acids may be used including the following:
Citric acid - monohydrous Citric acid - anhydrous Citric acid - hydrous Acetic acid Formic acid Ascorbic acid Aspartic acid Benzene sulphonic acid Benzoic acid Hydrochloric acid Sulphuric acid Phosphoric acid Nitric acid Tartaric acid Diatrizoic acid Glutamic acid Lactic acid Malefic acid Succinic acid 5 Due to its limited solubility in water, Taxol is usually prepared and administered in a vehicle containing cremophor ELTM (a polyethoxylated castor oil which acts as a solubilizer) and ethanol. A
commercially available solution supplied by Bristol-Myers Squibb (BMS) is formulated with these components and has a pH of 9.1.
As indicated above, the invention essentially teaches addition of an acid to a taxol formulation to adjust its pH into the range 1 to 8, preferably 5 to 7.
In a preferred procedure adopted by the applicant, which it will be clearly understood is non-limiting, the following steps were carried out:
Mixina Instructions Citric acid was dissolved in absolute alcohol, using a ratio of 8 mls of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes.
Cremophor EL was weighted out into the main mixing vessel.
Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid. Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes. The taxol was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of taxol. The slurried taxol was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol. Solution 3 was adjusted 5 to 75% of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes.
Exam~l a 1 A solution was prepared with the following formulation:
Formulation: (Sample 1) Cremophor EL 0.5 mL
Citric Acid (Anhydrous) 2.0 mg Taxol 6.0 mg Absolute Alcohol to 1.0 mL
The pH of this solution was determined as 6.1.
The stability of this sample was compared with a sample prepared by the formulation stated in the NCI
Taxol Clinical brochure (as follows) which had a pH of 9.1. (Sample 2) Sample 2 per mL
Taxol 6 mg Cremophor EL 0.5 mL
Absolute Alcohol to 1 mL
The solutions were filled into clear type 1 glass 5 mL vials and sealed with rubber bungs.
The solutions were stored at 40°C for 7 (seven) days and the stability results are shown in Table 1.
Sample 1 Sample 2 pH 6.2 9.0 Potency 96.6 86.7 Major individual 0.3% 5.1% impurity Total impurities 2.0% 12.2%
Clearly Sample 1 showed significantly increased stability over Sample 2.
Example 2 A solution was prepared with the following formulation:
Formulation: (Sample 3) Cremophor EL 0.5 mL
Taxol 6.0 mg Absolute Ethanol to 1 mL
pH adjusted to 6.6 with 1.OM Acetic Acid.
The solution was filled into clear type I glass 5 mL vials and sealed with rubber bungs.
The solution was stored at 40°C for 7 days.
The stability results obtained are compared to those seen with Sample 2.
Sample 3 Sample 2 pH 6.7 9.0 Potency 97.5 86.7 Major individual 0.3% 5.1% impurity Total impurities 2.3% 12.2%
Again the significantly superior stability of the formulation according to the invention (Sample 3) is evident.
It will be clearly understood that the invention in its general aspects is not limited to the specific details referred to hereinabove.
Clearly Sample 1 showed significantly increased stability over Sample 2.
Example 2 A solution was prepared with the following formulation:
Formulation: (Sample 3) Cremophor EL 0.5 mL
Taxol 6.0 mg Absolute Ethanol to 1 mL
pH adjusted to 6.6 with 1.OM Acetic Acid.
The solution was filled into clear type I glass 5 mL vials and sealed with rubber bungs.
The solution was stored at 40°C for 7 days.
The stability results obtained are compared to those seen with Sample 2.
Sample 3 Sample 2 pH 6.7 9.0 Potency 97.5 86.7 Major individual 0.3% 5.1% impurity Total impurities 2.3% 12.2%
Again the significantly superior stability of the formulation according to the invention (Sample 3) is evident.
It will be clearly understood that the invention in its general aspects is not limited to the specific details referred to hereinabove.
Claims (40)
1. An article of manufacture comprising a sealable container and a pharmaceutical formulation contained therein, said pharmaceutical formulation comprising taxol; a pharmaceutically-acceptable carrier; and an acid in sufficient amount to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for seven days and wherein said pharmaceutical formulation has been sealed in said container for at least seven days.
2. The article of manufacture of claim 1, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
3. The article of manufacture of claim 1 or 2, further comprising ethanol as a constituent thereof.
4. The article of manufacture of any one of claims 1 to 3, wherein said pharmaceutically-acceptable carrier is polyethoxylated caster oil.
5. The article of manufacture of any one of claims 1 to 4, wherein said pharmaceutical formulation is anhydrous.
6. The article of manufacture of any one of claims 1 to 5, wherein said acid is a mineral acid.
7. The article of manufacture of any one of claims 1 to 5, wherein said acid is an organic acid.
8. The article of manufacture of any one of claims 1 to 5, wherein said acid is acetic acid.
9. The article of manufacture of any one of claims 1 to 5, wherein said acid is citric acid.
10. The article of manufacture of claim 9, wherein said citric acid is anhydrous.
11. A composition of matter produced by the process of:
(a) obtaining a sealable container;
(b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid in sufficient amount to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for seven days;
(c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
(a) obtaining a sealable container;
(b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid in sufficient amount to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for seven days;
(c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
12. The composition of matter of claim 11, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
13. The composition of matter of claim 11 or 12, further comprising ethanol as a constituent thereof.
14. The composition of matter of any one of claims 11 to 13, wherein said pharmaceutically-acceptable carrier is polyethoxylated caster oil.
15. The composition of matter of any one of claims 11 to 14, wherein said pharmaceutical formulation is anhydrous.
16. The composition of matter of any one of claims 11 to 15, wherein said acid is mineral acid.
17. The composition of matter of any one of claims 11 to 15, wherein said acid is an organic acid.
18. The composition of matter of any one of claims 11 to 15, wherein said acid is acetic acid.
19. The composition of matter of any one of claims 11 to 15, wherein said acid is citric acid.
20. The composition of matter of claim 19, wherein said citric acid is anhydrous.
21. A composition of matter comprising a sealable container and a pharmaceutical formulation contained therein, said pharmaceutical formulation comprising taxol; a pharmaceutically-acceptable carrier; and an acid, said formulation being such that at least 95% of the taxol potency is retained when said formulation is stored at 40°C for seven days; and wherein said pharmaceutical formulation has been sealed in said container for at least seven days.
22. The composition of matter of claim 21, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
23. The composition of matter of claim 21 or 22, further comprising ethanol as a constituent thereof.
24. The composition of matter of any one of claims 21 to 23, wherein said pharmaceutically-acceptable carrier is polyethoxylated caster oil.
25. The composition of matter of any one of claims 21 to 24, wherein said pharmaceutical formulation is anhydrous.
26. The composition of matter of any one of claims 21 to 25, wherein said acid is mineral acid.
27. The composition of matter of any one of claims 21 to 25, wherein said acid is an organic acid.
28. The composition of matter of any one of claims 21 to 25, wherein said acid is acetic acid.
29. The composition of matter of any one of claims 21 to 25, wherein said acid is citric acid.
30. The composition of matter of claim 29, wherein said citric acid is anhydrous.
31. A composition of matter produced by the process of:
(a) obtaining a sealable container;
(b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid, said formulation being such that at least 95% of the taxol potency is retained when said formulation is stored at 40°C for seven days;
(c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
(a) obtaining a sealable container;
(b) obtaining a pharmaceutical formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acid, said formulation being such that at least 95% of the taxol potency is retained when said formulation is stored at 40°C for seven days;
(c) placing said pharmaceutical formulation in said sealable container;
(d) sealing said sealable container; and (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
32. The composition of matter of claim 31, wherein said pharmaceutical formulation has a pH between 5 and 7, inclusive.
33. The composition of matter of claim 31 or 32, further comprising ethanol as a constituent thereof.
34. The composition of matter of any one of claims 31 to 33, wherein said pharmaceutically-acceptable carrier is polyethoxylated caster oil.
35. The composition of matter of any one of claims 31 to 34, wherein said pharmaceutical formulation is anhydrous.
36. The composition of matter of any one of claims 31 to 35, wherein said acid is mineral acid.
37. The composition of matter of any one of claims 31 to 35, wherein said acid is an organic acid.
38. The composition of matter of any one of claims 31 to 35, wherein said acid is acetic acid.
39. The composition of matter of any one of claims 31 to 35, wherein said acid is citric acid.
40. The composition of matter of claim 39, wherein said citric acid is anhydrous.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL607492 | 1992-11-27 | ||
AUPL6074 | 1992-11-27 | ||
US99550192A | 1992-12-22 | 1992-12-22 | |
US07/995,501 | 1992-12-22 | ||
CA002149150A CA2149150C (en) | 1992-11-27 | 1993-11-18 | Injectable taxol composition with improved stability |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002149150A Division CA2149150C (en) | 1992-11-27 | 1993-11-18 | Injectable taxol composition with improved stability |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2308082A1 true CA2308082A1 (en) | 1994-06-09 |
Family
ID=25644377
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002149150A Expired - Lifetime CA2149150C (en) | 1992-11-27 | 1993-11-18 | Injectable taxol composition with improved stability |
CA002308082A Abandoned CA2308082A1 (en) | 1992-11-27 | 1993-11-18 | Injectable compostion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002149150A Expired - Lifetime CA2149150C (en) | 1992-11-27 | 1993-11-18 | Injectable taxol composition with improved stability |
Country Status (12)
Country | Link |
---|---|
US (7) | US5733888A (en) |
EP (4) | EP1384474A1 (en) |
JP (1) | JP2880292B2 (en) |
AT (2) | ATE169216T1 (en) |
AU (1) | AU5612694A (en) |
CA (2) | CA2149150C (en) |
DE (2) | DE69320206T2 (en) |
DK (2) | DK0835657T3 (en) |
ES (2) | ES2119996T3 (en) |
GR (1) | GR3027724T3 (en) |
PT (1) | PT835657E (en) |
WO (2) | WO1994012030A1 (en) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2119996T3 (en) * | 1992-11-27 | 1998-10-16 | Napro Biotherapeutics Inc | INJECTABLE COMPOSITION INCLUDING FACLITAXEL. |
TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
FR2710534B1 (en) * | 1994-09-28 | 1996-07-05 | Bristol Myers Squibb Co | Stabilization solvent, pharmaceutical composition containing it, and process for its preparation. |
NL9500340A (en) * | 1995-02-22 | 1996-10-01 | Yew Tree Pharmaceuticals B V | Stabilized paclitaxel solution and pharmaceutical preparation containing said solution |
DE19536165A1 (en) * | 1995-09-28 | 1997-04-03 | Basf Ag | Process for cleaning alkoxylated fats |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6395770B1 (en) | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
AU724842B2 (en) * | 1995-12-21 | 2000-09-28 | Genelabs Technologies, Inc. | Taxane composition and method |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US20030157187A1 (en) * | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
BR9713661A (en) | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulation and method for the treatment of neoplasms by inhalation |
US20030087954A1 (en) * | 1997-01-07 | 2003-05-08 | Sonus Pharmaceuticals, Inc. | Method of treating bladder carcinoma using a Taxane/Tocopherol formulation |
US20030105156A1 (en) * | 1997-01-07 | 2003-06-05 | Nagesh Palepu | Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6727280B2 (en) * | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
BE1011216A3 (en) * | 1997-06-13 | 1999-06-01 | Thissen En Abrege L T B Lab | Pharmaceutical form for the administration of paclitaxel, method of preparation of a composition paclitaxel ready to employment and use thereof. |
IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
US6388112B1 (en) | 1998-10-20 | 2002-05-14 | Ben Venue Laboratories, Inc. | Process for purification of solvents useful in the preparation of pharmaceutical compositions |
US6071952A (en) * | 1998-12-02 | 2000-06-06 | Mylan Pharmaceuticals, Inc. | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
ATE370928T1 (en) | 1999-05-14 | 2007-09-15 | Nereus Pharmaceuticals Inc | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR ALPHA MODULATORS, SYNTHESIS OF THESE MODULATORS AND METHODS OF APPLYING THESE MODULATORS |
DE19925211B4 (en) * | 1999-06-01 | 2006-01-12 | PBS Pharmaceutical Bulk Substances SA | Kit for the preparation of a formulation of paclitaxel |
EP1251845A1 (en) * | 2000-01-20 | 2002-10-30 | Baker Norton Pharmaceuticals, Inc. | Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof |
CZ20013498A3 (en) * | 2000-02-02 | 2002-04-17 | Florida State University Research Foundation, Inc. | Taxane formulations having enhanced solubility |
WO2001062919A1 (en) * | 2000-02-23 | 2001-08-30 | Aurora Biosciences Corporation | Modified fluorescent proteins |
US6951885B2 (en) | 2000-08-10 | 2005-10-04 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
JP4922507B2 (en) * | 2000-08-10 | 2012-04-25 | 武田薬品工業株式会社 | Pharmaceutical composition |
US7144723B2 (en) * | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
EP1337273A2 (en) * | 2000-11-28 | 2003-08-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
EP1379231A2 (en) | 2001-04-06 | 2004-01-14 | Cytorex Biosciences, Inc. | Pharmacologically active strong acid solutions |
KR100774366B1 (en) * | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | Injectable composition of paclitaxel |
EP1461056A4 (en) * | 2001-11-26 | 2006-01-25 | Supergen Inc | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
WO2003045357A1 (en) * | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
EP1465618A2 (en) * | 2001-12-20 | 2004-10-13 | Bristol-Myers Squibb Company | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
CZ294371B6 (en) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilized pharmaceutical composition based on polyoxyethylated castor oil and process for preparing thereof |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
EP2277507A1 (en) | 2002-06-26 | 2011-01-26 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
CN100540548C (en) * | 2002-08-02 | 2009-09-16 | 尼瑞斯药品公司 | Synthesizing of dehydrophenylahistin and analogue thereof and dehydrophenylahistin and analogue thereof |
US7919497B2 (en) * | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US7935704B2 (en) * | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
WO2004034970A2 (en) * | 2002-09-27 | 2004-04-29 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
EP1558241A2 (en) * | 2002-11-08 | 2005-08-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using taxane derivatives |
CA2515651A1 (en) * | 2003-02-11 | 2004-08-26 | Northwestern University | Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon |
NZ544588A (en) * | 2003-06-20 | 2010-06-25 | Nereus Pharmaceuticals Inc | Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
CN1823070A (en) * | 2003-06-20 | 2006-08-23 | 加利福尼亚大学董事会 | Salinosporamides and methods for use thereof |
US20050016926A1 (en) * | 2003-07-24 | 2005-01-27 | Dabur Research Foundation | Stabilized formulation |
US7619059B2 (en) * | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
CA2445420A1 (en) * | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7838551B2 (en) * | 2003-12-12 | 2010-11-23 | Quiral Quimica do Basil S.A. | Process for the preparation of concentrated, sterile injectable solutions containing docetaxel |
AU2005206560A1 (en) * | 2004-01-23 | 2005-08-04 | Nereus Pharmaceuticals, Inc. | Bis-indole pyrroles useful as antimicrobials agents |
KR20050099311A (en) * | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | Composition for injection comprising anticancer drug |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
AU2005283141B2 (en) * | 2004-04-30 | 2012-05-10 | Nereus Pharmaceuticals, Inc. | (3.2.0) heterocyclic compounds and methods of using the same |
US7361683B2 (en) | 2004-11-24 | 2008-04-22 | Yung Shin Pharm. Ind., Co., Ltd | Paclitaxel aqueous injection solution and methods for preparing the same |
PL1830838T3 (en) * | 2004-12-03 | 2013-07-31 | Dana Farber Cancer Inst Inc | Compositions and methods for treating neoplastic diseases |
WO2006126825A1 (en) * | 2005-05-23 | 2006-11-30 | Choongwae Pharma Corporation | Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection |
KR20080030024A (en) * | 2005-06-17 | 2008-04-03 | 호스피라 오스트레일리아 피티와이 리미티드 | Liquid pharmaceutical formulations of docetaxel |
AU2006276274B2 (en) | 2005-07-21 | 2012-03-29 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
NZ566705A (en) | 2005-08-31 | 2011-06-30 | Abraxis Bioscience Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
ZA200802765B (en) | 2005-08-31 | 2009-08-26 | Abraxis Bioscience Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
BRPI0600194A (en) * | 2006-01-30 | 2007-10-23 | Quiral Quimica Do Brasil S A | docetaxel-containing pharmaceutical compositions and a degradation inhibitor and process for obtaining same |
US8129527B2 (en) * | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US7824698B2 (en) * | 2007-02-02 | 2010-11-02 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of Salinosporamide A |
FR2912745A1 (en) * | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | NEW INDOLE-DERIVED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US20090017167A1 (en) * | 2007-07-11 | 2009-01-15 | Herbalife International Inc. | Mixture and beverage made therefrom for protecting cellular hydration |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
KR101053780B1 (en) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | Single liquid stable pharmaceutical composition containing docetaxel |
EP2276765A4 (en) * | 2008-05-12 | 2011-10-19 | Nereus Pharmaceuticals Inc | Salinosporamide derivatives as proteasome inhibitors |
ES2344674B1 (en) | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS. |
US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8128951B2 (en) * | 2008-09-15 | 2012-03-06 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8257722B2 (en) | 2008-09-15 | 2012-09-04 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8114429B2 (en) | 2008-09-15 | 2012-02-14 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
TWI438009B (en) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | Taxane pro-emulsion formulations and methods making and using the same |
EP2566474B1 (en) | 2010-05-03 | 2017-11-15 | Teikoku Pharma USA, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
EP2691075A1 (en) | 2011-03-29 | 2014-02-05 | Sanofi | Otamixaban formulations with improved stability |
US20140234345A1 (en) * | 2011-07-11 | 2014-08-21 | Biolyse Pharma Corporation | Novel anti-cancer isocarbostyril alkaloid conjugates |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
EP2777691A1 (en) | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
EP2968390A4 (en) * | 2013-03-15 | 2016-10-26 | Epizyme Inc | Injectable formulations for treating cancer |
US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
CA2959965A1 (en) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Pharmaceutical formulations comprising tetrahydrocurcumin and lipids |
JP2017527567A (en) * | 2014-09-17 | 2017-09-21 | エピザイム インコーポレイテッド | Injection formulation for the treatment of cancer |
EP3204120B1 (en) | 2014-10-08 | 2021-05-26 | Pacific Northwest Research Institute | Methods and compositions for increasing the potency of antifungal agents |
RU2728796C2 (en) | 2015-03-06 | 2020-07-31 | Бейондспринг Фармасьютикалс, Инк. | Method for treating a brain tumor |
CN107530341B (en) | 2015-03-06 | 2021-10-01 | 大连万春布林医药有限公司 | Methods of treating cancers associated with RAS mutations |
SG10202108194XA (en) | 2015-07-13 | 2021-09-29 | Beyondspring Pharmaceuticals Inc | Plinabulin compositions |
US10561766B2 (en) * | 2015-09-15 | 2020-02-18 | W. L. Gore & Associates, Inc. | Drug composition and coating |
CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
BR112018074990A2 (en) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composition, uses and method for reducing neutropenia |
US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
EP3576733A4 (en) | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
US10226423B1 (en) * | 2017-12-20 | 2019-03-12 | RxOMEG Therapeutics LLC | Colchicine drug-to-drug interactions |
WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
EP3773612A4 (en) | 2018-03-28 | 2022-01-12 | Herbalife International of America, Inc. | Acetylation of polysaccharides |
JP2022508807A (en) * | 2018-10-16 | 2022-01-19 | ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド | Intratumor injection product |
IL297015A (en) | 2020-04-13 | 2022-12-01 | US Nano Food & Drug INC | Basic chemotherapeutic intratumour injection formulation |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS552421B2 (en) * | 1971-08-06 | 1980-01-19 | ||
FR2601675B1 (en) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5157049A (en) * | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5136060A (en) * | 1989-11-14 | 1992-08-04 | Florida State University | Method for preparation of taxol using an oxazinone |
DE69113705T2 (en) * | 1990-02-15 | 1996-03-21 | Pq Corp | METHOD FOR TREATING FRYING OIL USING AN ALUMINUM OXIDE AND AMORPHOUS SILICONE COMPOSITION. |
TW223634B (en) * | 1991-03-18 | 1994-05-11 | Kingston David G I | |
FR2678833B1 (en) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS. |
US5254580A (en) * | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
US5281727A (en) * | 1992-11-27 | 1994-01-25 | Napro Biotherapeutics, Inc. | Method of using ion exchange media to increase taxane yields |
NZ258044A (en) * | 1992-11-27 | 1995-12-21 | Faulding F H & Co Ltd | Pharmaceutical composition comprising taxol, solubilising agent, an acid and an organic solvent |
ES2119996T3 (en) * | 1992-11-27 | 1998-10-16 | Napro Biotherapeutics Inc | INJECTABLE COMPOSITION INCLUDING FACLITAXEL. |
TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5733388A (en) | 1994-08-11 | 1998-03-31 | Daido Tokiushuko Kabushiki Kaisha | Steel composition for bearings and method of producing the same |
-
1993
- 1993-11-18 ES ES94901593T patent/ES2119996T3/en not_active Expired - Lifetime
- 1993-11-18 WO PCT/US1993/011199 patent/WO1994012030A1/en active Application Filing
- 1993-11-18 CA CA002149150A patent/CA2149150C/en not_active Expired - Lifetime
- 1993-11-18 EP EP03025151A patent/EP1384474A1/en active Pending
- 1993-11-18 EP EP97121710A patent/EP0835657B1/en not_active Revoked
- 1993-11-18 DE DE69320206T patent/DE69320206T2/en not_active Revoked
- 1993-11-18 EP EP94901593A patent/EP0674510B1/en not_active Revoked
- 1993-11-18 CA CA002308082A patent/CA2308082A1/en not_active Abandoned
- 1993-11-18 AU AU56126/94A patent/AU5612694A/en not_active Abandoned
- 1993-11-18 DE DE69333605T patent/DE69333605T2/en not_active Revoked
- 1993-11-18 AT AT94901593T patent/ATE169216T1/en not_active IP Right Cessation
- 1993-11-18 JP JP6513255A patent/JP2880292B2/en not_active Expired - Fee Related
- 1993-11-18 PT PT97121710T patent/PT835657E/en unknown
- 1993-11-18 AT AT97121710T patent/ATE274347T1/en not_active IP Right Cessation
- 1993-11-18 WO PCT/US1993/011209 patent/WO1994012031A1/en not_active Application Discontinuation
- 1993-11-18 DK DK97121710T patent/DK0835657T3/en active
- 1993-11-18 EP EP04020044A patent/EP1500393A1/en not_active Withdrawn
- 1993-11-18 DK DK94901593T patent/DK0674510T3/en active
- 1993-11-18 ES ES97121710T patent/ES2224200T3/en not_active Expired - Lifetime
-
1996
- 1996-01-31 US US08/594,478 patent/US5733888A/en not_active Expired - Lifetime
-
1997
- 1997-11-26 US US08/979,836 patent/US5977164A/en not_active Expired - Lifetime
-
1998
- 1998-02-24 US US09/028,906 patent/US5972992A/en not_active Expired - Lifetime
- 1998-08-26 GR GR980401904T patent/GR3027724T3/en unknown
-
1999
- 1999-07-19 US US09/356,158 patent/US6140359A/en not_active Expired - Fee Related
-
2000
- 2000-05-03 US US09/563,969 patent/US6306894B1/en not_active Expired - Fee Related
-
2001
- 2001-10-04 US US09/970,558 patent/US6770670B2/en not_active Expired - Fee Related
-
2004
- 2004-04-29 US US10/835,875 patent/US20040204479A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6140359A (en) | 2000-10-31 |
EP0674510A1 (en) | 1995-10-04 |
DE69320206T2 (en) | 1999-02-11 |
DE69320206D1 (en) | 1998-09-10 |
ATE274347T1 (en) | 2004-09-15 |
US5733888A (en) | 1998-03-31 |
EP1384474A1 (en) | 2004-01-28 |
DE69333605D1 (en) | 2004-09-30 |
DE69333605T2 (en) | 2005-02-03 |
EP0835657A1 (en) | 1998-04-15 |
ES2224200T3 (en) | 2005-03-01 |
AU5612694A (en) | 1994-06-22 |
JPH08503945A (en) | 1996-04-30 |
US6770670B2 (en) | 2004-08-03 |
EP0835657B1 (en) | 2004-08-25 |
EP0674510A4 (en) | 1995-08-12 |
JP2880292B2 (en) | 1999-04-05 |
ATE169216T1 (en) | 1998-08-15 |
WO1994012030A1 (en) | 1994-06-09 |
GR3027724T3 (en) | 1998-11-30 |
US20030065022A1 (en) | 2003-04-03 |
US5977164A (en) | 1999-11-02 |
US6306894B1 (en) | 2001-10-23 |
DK0835657T3 (en) | 2005-01-10 |
WO1994012031A1 (en) | 1994-06-09 |
ES2119996T3 (en) | 1998-10-16 |
PT835657E (en) | 2004-11-30 |
US5972992A (en) | 1999-10-26 |
CA2149150A1 (en) | 1994-06-09 |
US20040204479A1 (en) | 2004-10-14 |
EP1500393A1 (en) | 2005-01-26 |
DK0674510T3 (en) | 1999-05-10 |
CA2149150C (en) | 2000-08-01 |
EP0674510B1 (en) | 1998-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5733888A (en) | Injectable composition | |
KR100371062B1 (en) | Injectable taxi brush compositions with improved stability and methods of formulating them | |
JP4805599B2 (en) | Paclitaxel aqueous injection solution and preparation method thereof | |
KR20080030024A (en) | Liquid pharmaceutical formulations of docetaxel | |
HU217839B (en) | Novel methods for producing stabile medicaments containing taxane derivatives | |
CN101415416A (en) | Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same | |
IE51637B1 (en) | Pharmaceutical preparation | |
JP5334937B2 (en) | Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment | |
AU2002351169B2 (en) | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions | |
JP6292267B2 (en) | Docetaxel formulation | |
RU2279873C2 (en) | Vinorelbin-containing oral pharmaceutical composition for soft capsule and method for treatment | |
GB2388025A (en) | Kit for preparing a formulation of paclitaxel | |
KR20200005110A (en) | Methods for improving stability of pharmaceutical products containing a taxane-containing pharmaceutical composition | |
JP2018115178A (en) | Docetaxel formulation | |
EP1682119A1 (en) | Discodermolide compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |